http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
View Older Stories
-
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
-
Hannon Armstrong Appoints Former EXIM Chairman Kimberly A. Reed and CEO Jeffrey A. Lipson to Board of Directors
-
Takeda (TAK) and Arrowhead (ARWR) Report Topline Results from SEQUOIA Phase 2 Study of Fazirsiran
-
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
-
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
-
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
-
Takeda Pharmaceutical (TAK) and Arrowhead (ARWR) Announce Publication of Results from Phase 2 Study of Fazirsiran
-
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
-
NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL C
-
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
-
Poseida Therapeutics (PSTX) Enters Research Collaboration with Takeda (TAK) for Novel Non-Viral In Vivo Gene Therapies
-
Mirum Pharmaceuticals (MIRM), Takeda (TAK) Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
-
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
-
Evotec and Takeda (TAK) Enter Strategic RNA Targeting Drug Discovery and Development Alliance
-
Evotec and Takeda Enter Strategic RNA Targeting Drug Discovery and Development Alliance
-
The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases
-
Novavax (NVAX), Takeda (TAK) Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
-
Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)]
-
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
-
Takeda (TAK) and Arrowhead (ARWR) Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
-
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
-
Foundation Medicine (FMI), Takeda Announce Collaboration To Develop FoundationOne CDx and FoundationOne Liquid CDx as Companion Diagnostics for Takeda's Late-Stage Lung Cancer Portfolio
-
Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda’s Late-Stage Lung Cancer Portfolio
-
Novavax (NVAX) and Takeda (TAK) Announce Collaboration for Novavax' COVID-19 Vaccine Candidate in Japan
-
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
-
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
-
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
-
Takeda (TAK) Partners with Twist Bioscience (TWST) to Expand Biologics Discovery Capabilities
-
Seattle Genetics (SGEN), Takeda (TAK) Announce Additional Analyses of ADCETRIS ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at ASH
-
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
-
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
-
Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention to Improve Health in Developing and Emerging Countries
-
Taku Acquires Sonora Gulch Gold Project from Golden Predator in White Gold District of Yukon
-
Taku Acquires Strategic Properties from Golden Predator in White Gold District of Yukon
-
Taku acquires Keynote Gold Project in Keno Hill area of Yukon
-
Taku Gold Corp. Announces Closing of Financing
-
Taku Contemplating Mineral Property Acquisition from Golden Predator Mining Corp. in White Gold District of Yukon
-
Taku Gold Corp. Announces Closing of First Tranche of Financing
-
Taku Increases Financing to $1,500,000
-
Taku Increases Financing to $1,000,000
-
Taku Announces $500,000 Financing
-
Rosebute Agreement Terminated and Exploration Plans for 2017
-
Taku Announces $400,000 Flow-Through Financing
-
Taku Gold Joint Venture Partner, Independence Gold, Intersects Gold Mineralization at Rosebute Property, Yukon
-
Taku Identifies Gold-In-Soil Anomaly at McQ Property in Yukon
-
Taku Updates Exploration Activity in Yukon and Northern B.C.
-
Taku Acquires McQ Gold Property Proximate to Victoria Gold's Eagle Gold Project in the McQueston Gold District of Yukon
-
Taku Partner to Drill 1500 Metres on Rosebute Property
-
Taku Signs Rosebute Option Agreement With Independence Gold in Yukon
